Media Articles Related to Opana (Oxymorphone)
More resilient people tend to have a higher pain tolerance
Source: Anxiety / Stress News From Medical News Today [2014.09.13]
Resilience, a person's ability to overcome adverse circumstances, is the main quality associated with pain tolerance among patients and their adjustment to chronic pain.
Avoiding Pain Management Prosecutions
Source: Medscape NeurologyHeadlines [2014.09.12]
The key to staying out of court, says an attorney with years of experience in the field, is keeping up-to-date documentation.
Medscape Medical News
International Conference and Exhibition on Pain Medicine, June 08-10, 2015, Chicago
Source: Conferences News From Medical News Today [2014.09.12]
OMICS Group is pleased to invite you to participate in the International Conference and Exhibition on Pain Medicine during June 08-10, 2015 at Chicago, USA.
Groundbreaking study reveals best positions for sex for men who have back pain
Source: Sexual Health / STDs News From Medical News Today [2014.09.12]
Contrary to popular belief, spooning is not always the best sex position for those with a bad back, according to new research from the University of Waterloo.
OncoBriefs: New Myeloma Standard? Robotics and Pain (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2014.09.12]
(MedPage Today) -- Patients with newly diagnosed multiple myeloma lived longer and had significantly slower disease progression with a new two-drug regimen than with a long-time, standard three-drug regimen, a randomized trial showed.
Published Studies Related to Opana (Oxymorphone)
Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. [2011.05]
OBJECTIVE: To compare the subjective effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSIONS: At equianalgesic doses, single oral intact OM-ER produced lower positive, negative, and balance subjective effects than OC-CR, indicating that analgesic potency may not necessarily be reflected in subjective/objective effects.
Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. [2010.11]
BACKGROUND: Opioids provide effective pain control, yet have risks including adverse events (AEs) (e.g., constipation, nausea/vomiting, sedation) and cognitive/psychomotor effects. OBJECTIVE: To compare cognitive and psychomotor effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSION: Single oral intact low and high doses of OM-ER produced less cognitive and psychomotor impairment plus less sedation than equianalgesic OC-CR in this exploratory study. ClinicalTrials.gov registration NCT00955110.
Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. [2010.05]
OBJECTIVE: To evaluate the long-term safety, tolerability, and effectiveness of oxymorphone extended release (ER) in patients with cancer-related pain... CONCLUSIONS: In these patients with pain related to cancer, oxymorphone ER was generally well tolerated and provided stable long-term pain control.
The pain quality response profile of oxymorphone extended release in the treatment of low back pain. [2009.02]
OBJECTIVE: In controlled trials of analgesics, the primary outcome variable is most often a measure of global pain intensity. However, because pain is associated with a variety of pain sensations, the effects of analgesic treatments on different sensations could go undetected if specific pain qualities are not assessed...
Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. [2009.02]
OBJECTIVE: This study assessed the potential effects of age, sex, and prior opioid use on the response to oxymorphone extended release (ER) in patients with moderate to severe chronic low back pain... CONCLUSION: In the enriched population of patients who successfully titrated to oxymorphone ER, oxymorphone ER was effective and generally well tolerated, independent of patients' age, sex, or previous opioid use.
Clinical Trials Related to Opana (Oxymorphone)
Effect of Extended-Release Oxymorphone Taking With or Without Food on Cognitive Functioning [Recruiting]
The purpose of the study is to determine whether extended-release oxymorphone hydrochloride
taken orally with a high-fat meal, generating an approximately 50% higher Cmax, impacts
cognitive functioning, using Cambridge Neuropsychological Test Automated Battery (CANTAB)
tests, to a greater extent than when taking under conditions of fasting.
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects [Recruiting]
A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone [Recruiting]
This project will explore the safety and feasibility of performing a successful intravenous
patient controlled analgesia (IV PCA) Oxymorphone titration and conversion to oral ER
Oxymorphone (extended release or OPANA ER) in the outpatient setting.
Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects [Recruiting]
Patients will convert from current opioid to Oxymorphone ER and undergo titration. During
the Titration Period, subjects will receive daily oxymorphone Extended Release tablets(s)
every 12 hours. Dosing adjustments will be based on the review of the subject's pain
scores. Oxymorphone IR 5 mg will be provided to be used as supplemental "breakthrough" pain
medication (as needed). Titration Period will end when the fixed dose of study medication
is tolerated and the subject achieves adequate analgesia. Subjects will then proceed to the
open-label 3-month maintenance period on the fixed dose of study medication established
during the Titration Period.
Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects. [Recruiting]
When post-operative parenteral analgesia is discontinued, oral dosing with study medication
may begin once the subject has developed a moderate level of pain as defined by a 100 mm VAS
(pain intensity score greater than or equal to 40).
Reports of Suspected Opana (Oxymorphone) Side Effects
Drug Abuse (22),
Drug Ineffective (20),
Weight Decreased (15),
Drug Dependence (15),
Respiratory Depression (12),
Intentional Drug Misuse (11),
Pain (10), more >>